Clinical Trial Update: Dalpicilib-Enhanced Vs. Standard Endocrine Therapy in ER+ HER2- Early Breast Cancer [Phase 3]

View source ↗

Summary

This is a Phase 3 trial comparing dalpicilib-enhanced endocrine therapy with standard endocrine therapy for ER-positive, HER2-negative early breast cancer. The …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• Dalpicilib

Snippet

Sponsor: Fudan University | Conditions: Breast Cancer | Phase 3 | Status: ACTIVE_NOT_RECRUITING